文献速递神经肿瘤

双重资格医疗保险与医疗补助患者的脑肿瘤开颅手术结局:一项10年全国性分析

Brain tumor craniotomy outcomes for dual-eligible medicare and medicaid patients: a 10-year nationwide analysis.
PubMed 文献 · J Neurooncol · 2022-01-13

该研究分析2002至2011年全国住院患者样本中195725例因胶质瘤、脑膜瘤或转移瘤切除行开颅术的住院记录,其中双重资格患者占3.0%(n=5933)。双重资格患者较其他保险组出院去向不良率更高,且胶质瘤手术中并发症率和住院时间更高。作者认为需要实践和政策改革以改善这一脆弱临床人群的结局。

要点

  • 双重资格患者占开颅脑肿瘤切除住院的3.0%(n=5933),病情严重度和合并症评分更高。
  • 双重资格患者出院去向不良率高于所有其他保险组,且胶质瘤亚组并发症率和住院时间更高。
  • 双重资格患者死亡率低于自费患者(OR 0.47,P=0.017)。

核心结论

  • 双重资格患者脑肿瘤开颅术后出院去向不良率高于所有其他保险组,尤其在胶质瘤手术中并发症率和住院时间更高。
  • 作者认为需要实践和政策改革以改善这一脆弱临床人群的结局。

研究设计与样本

  • 回顾性队列研究,使用2002至2011年全国住院患者样本,纳入195725例因胶质瘤、脑膜瘤或转移瘤切除行开颅术的住院记录。
  • 采用多变量回归调整13项患者、严重度和医院特征,比较双重资格状态与四个参照保险组(仅 Medicare、仅 Medicaid、私人保险、自费)的结局关联。

主要发现

  • 双重资格患者占3.0%(n=5933),较仅 Medicare 患者年轻(P<0.001),但较仅 Medicaid、私人保险和自费患者年长(P<0.001)。
  • 双重资格患者病情严重度、死亡风险和 Charlson 合并症指数评分更高,且更多在低容量医院治疗(均 P<0.001)。
  • 双重资格患者死亡率低于自费患者(OR 0.47,P=0.017)。
  • 双重资格患者出院去向不良率高于仅 Medicare、仅 Medicaid、私人保险和自费患者(OR 分别为0.53、0.50、0.34和0.27,均 P<0.001)。
  • 双重资格患者并发症率(OR 1.23和1.20,均 P<0.05)和住院时间(β=1.06和1.13,均 P<0.01)高于仅 Medicare 和私人保险患者。

关键数值与推荐

  • 出院去向不良差异在三种肿瘤亚型中均显著,但仅胶质瘤双重资格患者继续表现出更高的并发症率和住院时间。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Dual-eligible (DE) patients, simultaneous Medicare and Medicaid beneficiaries, have been shown to have poorer clinical outcomes while incurring higher resource utilization. However, neurosurgical oncology outcomes for DE patients are poorly characterized. Accordingly, we examined the impact of DE status on perioperative outcomes following glioma, meningioma, or metastasis resection. METHODS: We identified all admissions undergoing a craniotomy for glioma, meningioma, or metastasis resection in the National Inpatient Sample from 2002 to 2011. Assessed outcomes included inpatient mortality, complications, discharge disposition, length of stay (LOS), and hospital costs. Multivariable regression adjusting for 13 patient, severity, and hospital characteristics assessed the association between DE status and outcomes, relative to four reference insurance groups (Medicare-only, Medicaid-only, private insurance, self-pay). RESULTS: Of 195,725 total admissions analyzed, 3.0% were dual-eligible beneficiaries (n = 5933). DEs were younger than Medicare admissions (P < 0.001) but older than Medicaid, private, and self-pay admissions (P < 0.001). Relative to other insurance groups, DEs also exhibited higher severity of illness, risk of mortality, and Charlson Comorbidity Index scores as well as treatment at low-volume hospitals (all P < 0.001). DEs had lower mortality than self-pay admissions (odds ratio [OR] 0.47, P = 0.017). Compared to Medicare, Medicaid, private, and self-pay admissions, DEs had lower rates of discharge disposition (OR 0.53, 0.50, 0.34, and 0.27, respectively, all P < 0.001). DEs also had higher complications (OR 1.23 and 1.20, respectively, both P < 0.05) and LOS (β = 1.06 and 1.13, respectively, both P < 0.01) than Medicare and private insurance beneficiaries. Differences in discharge disposition remained significant for all three tumor subtypes, but only glioma DE admissions continued to exhibit higher complications and LOS. CONCLUSIONS: DEs undergoing definitive craniotomy for brain tumor had higher rates of unfavorable discharge disposition compared to all other insurance groups and, especially for glioma surgery, had higher inpatient complication rates and LOS. Practice and policy reforms to improve outcomes for this vulnerable clinical population are warranted.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Tang OY, Clarke RA, Rivera Perla KM, et al. Brain tumor craniotomy outcomes for dual-eligible medicare and medicaid patients: a 10-year nationwide analysis. J Neurooncol. 2022. PMID: 35023004. doi:10.1007/s11060-021-03922-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。